Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

ABSTRACT Introduction Oral anticoagulants (OACs) are the cornerstone of stroke
prevention in atrial fibrillation (AF), but prescribing decisions in older people are …

Background Anticoagulation among patients with cancer and atrial fibrillation is challenging
due to elevated risk of bleeding and stroke. We characterized use of oral anticoagulants …

Several observational studies have compared the effectiveness and safety outcomes
between nonvitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists …

Objectives In a previous real-world study, rivaroxaban reduced the risk of stroke overall and
severe stroke compared with warfarin in patients with nonvalvular atrial fibrillation (NVAF) …

Background Recent reports suggest that direct oral anticoagulants (DOAC) may induce
different anticoagulant and profibrinolytic responses. We performed a head-to-head …

Introduction: Current evidence regarding the clinical outcomes of non-vitamin K oral
anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation (AF) and previous …

Introduction There is a paucity of real-world studies examining the risks of stroke/systemic
embolism (SE) and major bleeding (MB) among non-valvular atrial fibrillation (NVAF) …

Background The COVID-19 pandemic profoundly disrupted the delivery of medical care. It
remains unclear whether individuals diagnosed with new onset disease during the …

Study objective The COVID-19 pandemic disrupted multiple aspects of the health care
system, including the diagnosis and control of chronic conditions. This study aimed to …